Receptor BioLogix has acquired the cancer vaccine Insegia and other assets of Aphton Corp. in a Chapter 11 bankruptcy sale. Insegia, also known as G17DT, is a therapeutic cancer vaccine that has been extensively studied for its effects on cancers of gastrointestinal origin. The immunotherapeutic stimulates the body to produce antibodies that neutralize the peptide hormone, gastrin. No financial details were disclosed.
"Insegia has been clinically studied in very difficult forms of cancer," said Thomas A. Glaze, CEO of Receptor BioLogix. "In view of the promising clinical trial results to date, we believe there is a strong likelihood Insegia has a beneficial effect on these cancers and warrants further clinical development. In addition, the available mechanisms for expedited regulatory approval in the United States and Europe will be pursued."
- take a look at the release on the buyout